Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04193553
Recruitment Status : Recruiting
First Posted : December 10, 2019
Last Update Posted : October 5, 2020
Sponsor:
Information provided by (Responsible Party):
Centre Leon Berard

Tracking Information
First Submitted Date  ICMJE December 5, 2019
First Posted Date  ICMJE December 10, 2019
Last Update Posted Date October 5, 2020
Actual Study Start Date  ICMJE January 17, 2020
Estimated Primary Completion Date September 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 9, 2019)
Progression-Free Survival (PFS) [ Time Frame: Up to 30 months ]
PFS, defined as the time from the date of randomisation to the date of the first documented radiological progression (RECIST 1.1) or death due to any cause. PFS will be estimated using the Kaplan-Meier method and will be described in terms of median PFS per arm, and hazard ratio for progression between the 2 arms. Associated 2-sided 95% CI for the estimates will be provided.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 9, 2019)
  • Overall Survival (OS) [ Time Frame: Up to 30 months ]
    OS, is defined as the time from the date of randomisation until the date of death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.
  • Objective Response Rate (ORR) for patient in the blinded part of the study [ Time Frame: Up to 30 months ]
    ORR, is the proportion of patients with a Complete Response or Partial Response as Best Overall Response.
  • Best Overall Response (BOR) for patient in the blinded part of the study [ Time Frame: Up to 30 months ]
    BOR, is described as the proportion of patients with a best overall response of Complete Response, Partial Response, Stable Disease or Progressive Disease.
  • Quality of Life (QoL) for patient in the blinded part of the study [ Time Frame: Up to 30 months ]
    QoL, will be assessed using the EORTC QLQ-C30. Scores will be calculated at each time point according to the scoring manuals. Descriptive statistics will be used to evaluate baseline scores and evolution of scores from baseline to each time point. Data will be compared between arms using the Student's t-test.
  • Patient's tolerance to treatment [ Time Frame: Up to 30 months ]
    The safety will be described mainly on the frequency of adverse events coded using the common toxicity criteria (NCI-CTCAE v5.0) grade. Descriptive statistics will be provided for characterizing and assessing patient tolerance to treatment. Adverse events will be coded according to the MedDRA®.
  • Progression-Free Survival (PFS) In patients from the placebo arm who switched into the active treatment group [ Time Frame: Up to 30 months ]
    OS, is defined as the time from the date of randomisation until the date of death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: October 1, 2020)
  • Mutation profile : KIT [ Time Frame: Inclusion ]
    Determined by immunohistochemistry (archival formalin fixed paraffin embedded tumor sample)
  • Mutation profile: PDGFR [ Time Frame: Inclusion ]
    Determined by immunohistochemistry (archival formalin fixed paraffin embedded tumor sample)
  • Pharmacokinetic properties of lenvatinib for patient in the blinded part of the study [ Time Frame: Inclusion, Day 1 of cycles 2, 3, 4, 5, up to 12 months (28 days cycle) ]
    Trough levels of lenvatinib
Original Other Pre-specified Outcome Measures
 (submitted: December 9, 2019)
  • Mutation profile : KIT [ Time Frame: Inclusion ]
    Determined by immunohistochemistry (archival formalin fixed paraffin embedded tumor sample)
  • Mutation profile: PDGFR [ Time Frame: Inclusion ]
    Determined by immunohistochemistry (archival formalin fixed paraffin embedded tumor sample)
 
Descriptive Information
Brief Title  ICMJE Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure
Official Title  ICMJE A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib
Brief Summary The primary objective is to compare the efficacy of lenvatinib plus Best Supportive Care versus Placebo plus Best Supportive Care in the treatment of patients with advanced GIST, after failure of imatinib and sunitinib.
Detailed Description

Even though the prognosis of advanced GIST has been tremendously improved by the introduction of tyrosine kinase inhibitors, the vast majority of patients will develop secondary resistance to these agents.

The therapeutic options of patients with advanced GIST with resistance (or intolerance) to imatinib and sunitinib remain then very limited and prognosis of patients are very poor.

Nilotinib has an inferior activity in first line setting as compared to imatinib. Sorafenib has been evaluated in off-label and compassionate use studies with a median PFS close to 3 to 4 months, and a median overall survival close to 9 months with few prolonged tumor control and limited availability.

Regorafenib was tested in a phase II and a randomized phase III trial (GRID) in this setting , and provided a significant PFS advantage with no significant improvement in OS.

There are no recognized standard options in patients whose tumors progress after 3 or more TKIs. The recently updated guidelines from ESMO in 2014, included the reintroduction of imatinib in an attempt to control the progression of the sensitive cell clones, and on the basis of the results of the RIGHT study.

This is therefore a situation with a clear unmet medical need.

Lenvatinib is a broad spectrum TKI targeting oncogenes KIT and RET and receptor tyrosine kinases, PDGFRA, VEGFR 1-3 and FGFR 1-4. It has demonstrated activity in iodine resistant metastatic thyroid cancers. Whether lenvatinib would be a useful agent in patients with GIST is not known but there is a rationale to investigate its activity in patients with advanced GIST.

In the present study, we propose to analyze the antitumor activity of lenvatinib in patients with GIST failing to at least imatinib and sunitinib in a randomized setting, vs placebo.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Gastro Intestinal Stromal Tumour
Intervention  ICMJE
  • Drug: Lenvatinib

    Lenvatinib will be administered continuously but patient's follow-up visits will be scheduled monthly.

    The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for dose reductions will be respected according to BI Lenvatinib.

    If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.

    Study treatments will be continued until a treatment discontinuation criteria is met.

  • Drug: Placebo

    Placebo will be administered continuously but patient's follow-up visits will be scheduled monthly.

    The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for placebo dose reductions are the same as for Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.

    Study treatments will be continued until a treatment discontinuation criteria is met.

    In case disease progression, patients in control arm could switch in the Lenvatinib + BSC arm.

  • Other: Best supportive care
    At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy…
Study Arms  ICMJE
  • Experimental: Lenvatinib + Best Supportive Care
    Interventions:
    • Drug: Lenvatinib
    • Other: Best supportive care
  • Placebo Comparator: Placebo + Best Supportive Care
    Interventions:
    • Drug: Placebo
    • Other: Best supportive care
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 9, 2019)
74
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 2023
Estimated Primary Completion Date September 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

I1. Male or female ≥ 18 years at the day of consenting to the study.

I2. Patient must have histologically confirmed diagnosis of GIST.

I3. Disease must be locally advanced or metastatic.

I4. Patient who failed (disease progression and/or intolerance) previously at least to imatinib and sunitinib.

Nota Bene: patients with more than 2 previous anticancer treatments are eligible.

I5. Patient must have evidence of measurable disease as per the RECIST version 1.1 (Appendix 2).

I6. Patient must have documented disease progression. I7. ECOG performance status 0, 1 or 2 (Appendix 3).

I8. Patient must have normal organ and bone marrow function as defined below:

  • Hematologic

    • Absolute neutrophil count (ANC) ≥ 1.5 Gi/L
    • Haemoglobin ≥ 9 g/dl (5.6 mmol/l) (subjects may not have had a transfusion within 7 days of screening assessment)
    • Platelets ≥ 100 Gi/l
  • Coagulation panel

    • Prothrombin time (PT) or international normalized ratio (INR) ≤ 1.2 X upper limit of normal (ULN)
    • Partial thromboplastin time (PTT) ≤ 1.2 X ULN Subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation.
  • Hepatic

    • Total bilirubin ≤ 1.5 X ULN
    • AST and ALT ≤ 2.5 X ULN
  • Renal

    • Serum creatinine ≤ 1.5 mg/dl (133 µmol/l) Or, if greater than 1.5 mg/dl: calculated creatinine clearance ≥ 50 ml/min
    • Urine Protein to Creatinine ratio (UPC) < 1; If UPC > 1, then a 24-hour urine protein must be assessed. Subjects must have a 24-hour urine protein value <1g.

I9. Patient and his/her partner using an effective contraception as defined in Appendix 1.

I10. Patient able to understand and willingness for follow-up visits. I11. Patient covered by a medical insurance. I12. Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to any study-specific procedure.

Exclusion Criteria:

E1. Patient with a documented mutation in PDGFRA exon 18 (D842V substitution).

E2. Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:

  • Active peptic ulcer disease
  • Known intraluminal metastatic lesions with risk of bleeding
  • Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment
  • Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:
  • Malabsorption syndrome
  • Major resection of the stomach or small bowel.

E3. Any active/uncontrolled infection, including known infection with HIV, Hepatitis B or Hepatitis C.

E4. Corrected QT interval (QTc) > 480 msecs using Bazett's formula

E5. History of any one or more of the following cardiovascular conditions within the past 6 months prior to the first dose of study drug:

  • Cardiac angioplasty or stenting
  • Myocardial infarction
  • Unstable angina
  • Coronary artery bypass graft surgery
  • Symptomatic peripheral vascular disease
  • Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) classification.

E6. Poorly controlled arterial hypertension (Systolic blood pressure: 150mmHg / Diastolic blood pressure: 90mmHg).

Note: Patients with high blood pressure can be enrolled provided that the hypertension is well controlled at a stable dose of antihypertensive therapy for at least 1 week prior to lenvatinib start).

E7. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major).

E8. Evidence of active bleeding or bleeding diathesis. E9. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.

E10. Clinically significant haemoptysis within 8 weeks of first dose of study drug.

E11. Any serious and/or unstable pre-existing medical, psychiatric, or other condition (geographic, social…) that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.

E12. Unable or unwilling to discontinue use of prohibited medications list in Section 6.3 for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study.

E13. Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia.

E14. Inability to swallow E15. Any contraindication to Lenvima®, according to its Summary of Product Characteristics E16. History of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition of lenvatinib E17. Clinically significant unrelated systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results.

E18. Pregnant or breastfeeding women. Women of childbearing potential (Appendix 1) are required to have a negative serum pregnancy test within 72 hours prior to study treatment start. A positive urine test must be confirmed by a serum pregnancy test Note: Female if applicable, subjects should discontinue breast-feeding prior to the first dose of study drug and should refrain from breastfeeding throughout the treatment period and for 14 days following the last dose of study drug.

E19. Patient under tutorship or curatorship.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Julien GAUTIER +33 4.26.55.68.29 julien.gautier@lyon.unicancer.fr
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04193553
Other Study ID Numbers  ICMJE ET18-291 - LENVAGIST
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Centre Leon Berard
Study Sponsor  ICMJE Centre Leon Berard
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Axel LE CESNE, Ph Gustave Roussy, Cancer Campus, Grand Paris
PRS Account Centre Leon Berard
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP